Full Description
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Contents
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.
-
- 電子書籍
- 時刻表復刻版1970年8月号
-
- 電子書籍
- イムリ 2 ビームコミックス
